RIPK3 and neoplasm: Due to the low percentage of cases with tumor cells with positive immunoreaction for RIPK3, the ROC and AUC for this marker have not been calculated, while for AXL, an exploratory cutoff of 27.5% of positive tumor cells has been calculated with the Youden criteria.